Drug Type Small molecule drug |
Synonyms Dexanabinone, Sinnabidol, ETS-2101 + [4] |
Target |
Mechanism NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC25H38O3 |
InChIKeySSQJFGMEZBFMNV-PMACEKPBSA-N |
CAS Registry112924-45-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Dexanabinol | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Brain Injuries, Traumatic | Phase 3 | - | 01 Jan 2001 | |
Brain Injuries, Traumatic | Phase 3 | - | 01 Jan 2001 | |
Brain Injuries | Phase 3 | US | - | |
Brain Injuries | Phase 3 | EU | - | |
Brain Injuries | Phase 3 | AU | - | |
Brain Injuries | Phase 3 | IL | - | |
Brain Injuries | Phase 3 | - | - | |
Cognitive Dysfunction | Phase 2 | IL | - | |
Cognitive Dysfunction | Phase 2 | - | - | |
Advanced cancer | Phase 1 | DE | 01 Apr 2015 |
NCT01654497 (Pubmed) Manual | Phase 1 | 26 | xtvdyztedb(fzskzjuywu) = krmappainm fafiaqkwij (onwotakgkn ) View more | Positive | 15 Feb 2021 | ||
Phase 1 | 40 | Cremophor+Dexanabinol (Dexanabinol 2 mg/kg) | pfqfochcbz(twgnsuoehg) = qwujfwbsbq hjvwddhyit (viadernnxk, ivitzwdocv - zpablmkqlc) View more | - | 18 Oct 2016 | ||
Cremophor+Dexanabinol (Dexanabinol 3 mg/kg) | pfqfochcbz(twgnsuoehg) = lqngrzqtsp hjvwddhyit (viadernnxk, zevhldywgd - rayzvhcgqe) View more |